A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show the treatment is safe and can significantly improve vision, even in severely affected patients.
Medical professionals are getting closer to developing a risk biomarker that will let them know which of their paediatric stem cell transplant patients are most likely to have sinusoidal obstruction syndrome (SOS), a potentially lethal side effect.